In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients.

Daiichi Sankyo has exclusive rights to further develop and commercialise gatipotuzumab as an antibody-drug conjugate (ADC). Image Credit: Photographer: Kentaro Takahashi/Bloomberg via Getty Images ...

Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein that acts as an intracellular calcium signal transducer, frequently overexpressed in cancer and associated with poor ...

Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India ...

The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...

MIT’s new AI model predicts antibody structures with greater accuracy ... Identifying a variety of good candidates early in the development process could help drug companies avoid spending a lot of ...

Co., Ltd. (“MediLink”) to use MediLink’s TMALIN ® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.